Listening to the People who live and support those with Parkinson’s we know they are looking for better treatments in years not decades and quality services as standard. This is at the heart of our strategy and we are now supporting and developing ground breaking new partnerships in research and services to make this happen.
THE EXCELLENCE NETWORK
The UK Parkinson's Excellence Network brings together health and social care professionals to transform care for people affected by Parkinson's.
enables professionals to work together for change
builds an expert workforce
equips professionals to influence services
strengthens the voice of people affected
The Excellence Network offers resources to support service improvement and engage people affected by Parkinson's, comprehensive information about education and training and collaboration opportunities.
How does Parkinson’s UK enable people to feel in control of life with Parkinson’s?
Being diagnosed with Parkinson’s can turn life upside down. And as symptoms develop over time it can affect every aspect of daily living. People tell us they are left feeling unable to plan for the future and like they are no longer in charge.
But no one has to face Parkinson’s alone. Parkinson’s UK is here to make sure everyone has what they need to take back control.
We know our services make a huge difference for people living with Parkinson’s. But our challenge now is to connect them to every single person with Parkinson’s, and their families, across the UK. We want to be there for people, right from diagnosis. We want to make sure everyone affected by Parkinson’s, at every stage, gets the information, local opportunities and inspiration from others that they need to live life to the full.
FINDING A CURE
Our commitment to research has resulted in Parkinson’s UK becoming the largest charitable funder of Parkinson’s research in Europe. We have been selecting and supporting projects at the drug discovery, preclinical and early clinical development stages. Our virtual approach means we can flexibly and creatively work with leading research organisations: clinical and academic institutions, pharmaceutical companies and biotechs worldwide, that can work with us in a results focused, efficient way to develop and commercialise new treatments for Parkinson’s.
The largest charity funder of Parkinson's research in Europe, we've invested over £80 million in developing treatments and a cure.
We're adopting a radical new approach - tackling the critical road blocks, filling the gaps and investing in big ideas that will speed up the process and deliver treatments to the people who need them, faster.
PARKINSON'S VIRTUAL BIOTECH
Now we're at a tipping point. Decades of research have unlocked key discoveries that could transform lives.
That's why we've created the Parkinson's Virtual Biotech, to fast track the most promising research and accelerate the development of new treatments.
Parkinson’s Virtual Biotech is the drug discovery and development arm of Parkinson’s UK, the largest charitable funder of Parkinson's research in Europe.
Our mission is to apply £2-4million of annual funding (totalling £11million by the end of 2019) raised by Parkinson's UK donors to support projects and companies that are driving towards important new treatments with the potential to transform the lives of people with Parkinson’s.
We are hoping to create a portfolio of projects that can attract further investment, and we’ll look to partner with companies to take successful projects into the later stages of drug development and trials.
Unlike our traditional research grants, projects supported within the Virtual Biotech are managed and developed in partnership with Parkinson's UK.
We select and manage projects at the drug discovery, preclinical and early clinical development stages.
Our virtual approach means we can work flexibly and creatively with leading research organisations - clinical and academic institutions, pharmaceutical companies and biotechs worldwide - that can work with us in a results-focused, efficient way to develop and commercialise new treatments for Parkinson's.